Therefore, the study made by Li et al. (2019) demonstrated that 2-Ethoxystypandrone was able to block the STAT3 activation (7.75 ± 0.18 μM, using 50% concentration) to induce the death of hepatocellular carcinoma and to inhibit the proliferation of cancer cells (IC50 = 2.70 ± 0.28 μM) [107]. Here, STAT3 is linked to hepatocellular carcinoma.